Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma

Inclusion criteria

(Before the trial, subjects must meet all of the requirements listed below in order to be enrolled)

• 18 to 80 years old;
• Stage IV pancreatic ductal adenocarcinoma with distant metastases confirmed by clinical, imaging, and pathology, and the primary and metastatic mass can be measured on imaging.
• No treatment history of chemotherapy, radiotherapy, or surgery
• Expected survival > 6 months
• ECGO score of 0-2
• Eligible for chemotherapy (white blood cell > 3.5×109/L, neutrophil value > 1.5×109/L, hemoglobin > 80g/L, platelets > 100×109/L, albumin > 25g/L, alanine aminotransferase or aspartate aminotransferase ≤ 3 times the upper limit of normal and total bilirubin level ≤ 34.2umol/L, creatinine < 176.8 umol/L, normal ECG)
• Signed written informed consent;

Exclusion criteria

• Contraindication of EUS-guide procedure or technical infeasibility (e.g.,coagulation disorder, anatomical changes, large vessels along the puncture path)
• Pregnant or breastfeeding
• Presence of brain metastases
• Presence of deep vein thrombosis or pulmonary embolism
• Presence of HIV, HBV, HCV infection or other uncontrollable active infection
• Hypersensitivity to chemotherapy drugs
• History of other malignancies within 5 years
• Peripheral neuropathy or interstitial lung disease within 5 years
• Patient is enrolled in any other clinical protocol or investigational trial.